

# AOD- 9604




**Burn Fat. Not Muscle.**

**The Precision Fat-Loss Peptide.**

FAT OXIDATION · NO IGF-1 · LEAN MUSCLE SPARING · FDA GRAS

AOD-9604 is a synthetic fragment of **human growth hormone** — specifically the C-terminal portion from amino acids 176–191 — engineered to isolate the fat-metabolising properties of hGH without any of its growth-promoting or insulin-desensitising side effects. It directly activates **lipolysis** (fat breakdown) and inhibits **lipogenesis** (fat storage), producing targeted fat loss while preserving lean muscle mass and carrying no risk of raising IGF-1 levels.



**16**

AMINO ACIDS

**No**

IGF-1 EFFECT

**GRAS**

FDA DESIGNATED

**Targeted**

FAT-ONLY ACTION

# What Is AOD-9604?

The fat-burning fragment of growth hormone — all the benefit, none of the baggage


## Carved from Growth Hormone — The Elegant Solution

Human growth hormone (hGH) has long been known to stimulate fat breakdown — but using full hGH for this purpose carries significant downsides: raised IGF-1 levels, insulin resistance, risk of unwanted tissue growth, and cost. Researchers at Monash University identified that the fat-metabolism properties of hGH reside almost entirely within **residues 176–191** — a 16-amino acid C-terminal fragment. AOD-9604 (Advanced Obesity Drug) is the synthetic version of this fragment, retaining all the lipolytic potency of hGH with none of its systemic growth effects.

## Dual Action — Ignite Fat Burning, Block Fat Storage

AOD-9604 works through two complementary mechanisms. First, it directly stimulates **lipolysis** — binding to the  $\beta$ 3-adrenergic receptor to activate adenylate cyclase, raising cAMP levels, and activating hormone-sensitive lipase (HSL), which breaks down stored triglycerides into free fatty acids for energy. Second, it inhibits **lipogenesis** — blocking the enzymes responsible for converting dietary carbohydrates into fat for storage. The result is a dual metabolic squeeze on adipose tissue: more fat burned, less fat made.

### The Science at a Glance



- No IGF-1 Elevation**

Unlike full hGH, AOD-9604 does not raise IGF-1 — eliminating the risk of insulin resistance, organomegaly, and unwanted tissue growth.
- Muscle Sparing**

Fat-specific mechanism preserves lean muscle mass during weight loss — unlike many caloric deficit protocols that cause muscle wasting.
- FDA GRAS Status**

AOD-9604 has been granted Generally Regarded As Safe (GRAS) status by the FDA — a significant regulatory milestone for a peptide agent.
- Cartilage & Joint Benefits**

Emerging research suggests AOD-9604 may support cartilage repair and has been investigated for osteoarthritis — a bonus benefit beyond fat loss.

### ★ THE ONLY PEPTIDE DESIGNED PURELY FOR FAT

AOD-9604 is unique in that its entire structure was engineered with one goal — selective fat metabolism. Every other major fat-loss peptide or drug achieves fat loss as a secondary effect of reducing appetite. AOD-9604 goes directly to the adipose tissue itself, making it a fundamentally different and complementary tool in the metabolic medicine toolkit.

# The Benefits of AOD-9604

Targeted fat oxidation — no growth effects, no muscle loss, no compromises

## 01 Targeted Fat Oxidation

AOD-9604 directly activates lipolysis in adipose tissue — particularly targeting stubborn visceral and subcutaneous fat deposits — without affecting lean muscle mass or overall body composition metrics beyond fat reduction.

## 02 No IGF-1 or Growth Effects

Because AOD-9604 lacks the GH receptor binding domain, it does not stimulate IGF-1 production, does not cause insulin resistance, and carries none of the growth-related risks associated with full hGH therapy — making it one of the safest fat-loss peptides available.

## 03 Inhibition of New Fat Storage

Beyond burning existing fat, AOD-9604 blocks lipogenesis — the process by which excess carbohydrates and calories are converted into new fat stores — helping prevent fat regain alongside promoting existing fat loss.

## 04 Lean Muscle Preservation

Clinical and preclinical studies confirm that AOD-9604 achieves fat reduction without catabolising muscle tissue — a key advantage over caloric restriction and many other weight-loss approaches that result in significant lean mass loss.

## 05 FDA GRAS Designation

AOD-9604 holds Generally Regarded As Safe (GRAS) status from the FDA — a regulatory designation that speaks to its excellent safety profile and sets it apart from the majority of research peptides.

## 06 Cartilage Repair & Joint Health

Beyond its metabolic role, AOD-9604 has demonstrated promising effects on cartilage regeneration in osteoarthritis models — reducing cartilage degradation and promoting repair, potentially offering a dual benefit for overweight patients with joint problems.

## 07 Complementary to GLP-1 Protocols

Because AOD-9604 acts directly on adipose tissue rather than appetite centres, it is mechanistically distinct from — and therefore complementary to — GLP-1 agonists and amylin analogues, making it a versatile addition to combination protocols.

## 08 Proven Safety in Human Trials

Multiple phase 1 and phase 2 clinical trials have confirmed AOD-9604's safety in humans, with no significant adverse events observed at therapeutic doses and a tolerability profile that makes it suitable for longer-term use.

AOD-9604 solves a problem no other peptide addresses: how to burn fat precisely, without growth signals, without losing muscle, and without affecting appetite pathways. It is the only peptide purpose-built for one target — and it hits that target with remarkable precision.

**Important:** AOD-9604 holds FDA GRAS status as a food ingredient but is not approved as a drug for any medical indication. It is classified as a research compound in many jurisdictions. All clinical data cited are from published studies. Use only under the supervision of a qualified healthcare professional.